Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. - Wikidata - awgldk - TriplyDB

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

http://www.wikidata.org/entity/Q33767281

about

Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome.

P2860

Q46140178-DBAB7494-6EAA-42C4-B65B-BCFCF8BE3F3D

P2860

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

http://www.wikidata.org/entity/Q33767281

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Early virologic response to ab ...... tricitabine during ACTG A5202.

@ast

Early virologic response to ab ...... tricitabine during ACTG A5202.

@en

type

label

Early virologic response to ab ...... tricitabine during ACTG A5202.

@ast

Early virologic response to ab ...... tricitabine during ACTG A5202.

@en

prefLabel

Early virologic response to ab ...... tricitabine during ACTG A5202.

@ast

Early virologic response to ab ...... tricitabine during ACTG A5202.

@en

P1433

Q33767281-83166AB4-52C2-4C2A-A615-EFDE49FFACA5

P1476

Q33767281-8847C27B-488A-4959-9189-87C1DFD1A681

P2093

Q33767281-1215BAE7-53F5-49E1-B4EE-FF807EFFD029

Q33767281-36A926B6-AF72-4DF7-8DD7-36D48D1CD3D1

Q33767281-58061F11-0CC8-4C81-B45D-F52C9984A780

Q33767281-7433B326-C4F1-47C8-A3AA-D71485657F44

Q33767281-7CA04DB5-B317-457E-97FD-B5CC44BEA5DA

Q33767281-8A169FCB-A55F-491C-8AF1-A90B885BCEAE

Q33767281-962D4E71-9863-4279-B5D9-C62F3EA02F0A

Q33767281-969BA568-6C43-4265-BF8A-D96E48C6B45F

Q33767281-E0E59269-0BC4-44C8-8B5B-2AD6ACF0AED2

Q33767281-FD3F17FE-0C59-4EA4-B4F8-F0CDE0295E85

P2860

Q33767281-23F1A1B7-5FB9-4E6C-B282-157AEEA62362

Q33767281-2FFDC3A1-20BC-40F6-91BD-61A3F023712F

Q33767281-3A28EAD7-E529-4714-A050-C999891F64CA

Q33767281-3C608BDB-8FA4-41F8-943E-6DDE4F1B2702

Q33767281-3EFAAC18-7EA0-4035-8DF3-F5D1D32152EC

Q33767281-5149BCE0-4950-41B0-80C6-F6C963B846CA

Q33767281-65BF9C91-9824-42BC-8B85-CEAF81798D08

Q33767281-66FF9E19-F49B-4CC7-8D50-B310B4AAEF07

Q33767281-6C8CD800-FC02-4765-98F3-5365815AC08B

Q33767281-6E20C84E-A176-4001-9DDC-504C67C9455A

P304

Q33767281-5FBEC8A9-981C-4368-8CF3-5954625513CF

P31

Q33767281-290181EA-2DF9-4088-910D-8A425404010B

P356

Q33767281-8AF436E4-B5C9-4A6F-95CB-A07B47D1722D

P433

Q33767281-E686352A-6228-4FC7-99C0-615E7A40FE9D

P478

Q33767281-C7A43D23-7ABB-4655-B7B0-7FE5CCC9F452

P577

Q33767281-71D449CC-50A8-4EEC-A7D5-10B3C102F127

P698

Q33767281-C55115FC-EF61-457C-BCC1-56425D9259F6

P921

Q33767281-0735E160-4A8C-4D88-9E54-072D0D0A3396

P932

Q33767281-B8629EED-C184-477B-89EE-9CBBFBDC7F1F

P356

P1433

HIV Clinical Trials

P1476

Early virologic response to ab ...... tricitabine during ACTG A5202.

@en

P2093

Andrew R Zolopa

http://www.w3.org/2001/XMLSchema#string

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Camlin Tierney

http://www.w3.org/2001/XMLSchema#string

Chakra Budhathoki

http://www.w3.org/2001/XMLSchema#string

David Katzenstein

http://www.w3.org/2001/XMLSchema#string

Eric S Daar

http://www.w3.org/2001/XMLSchema#string

Margaret A Fischl

http://www.w3.org/2001/XMLSchema#string

Maya Balamane

http://www.w3.org/2001/XMLSchema#string

Paul E Sax

http://www.w3.org/2001/XMLSchema#string

Philip M Grant

http://www.w3.org/2001/XMLSchema#string

P2860

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV inf

Class-sparing regimens for initial treatment of HIV-1 infection.

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.

P304

284-291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HCT1403-284

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24334181

http://www.w3.org/2001/XMLSchema#string

P921

P932

4060613

http://www.w3.org/2001/XMLSchema#string